Jaime R Merchan Selected Research

Therapeutics

1/2023	Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
1/2021	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
1/2019	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
1/2015	In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
1/2014	Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
4/2013	A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
3/2013	Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
6/2006	Sunitinib in patients with metastatic renal cell carcinoma.
6/2005	Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jaime R Merchan Research Topics

Disease

27	Neoplasms (Cancer) 11/2023 - 03/2003
10	Renal Cell Carcinoma (Grawitz Tumor) 11/2023 - 06/2006
5	Pancreatic Neoplasms (Pancreatic Cancer) 02/2018 - 05/2012
4	Hypoxia (Hypoxemia) 10/2021 - 05/2013
4	Neoplasm Metastasis (Metastasis) 01/2015 - 11/2005
3	Carcinogenesis 11/2023 - 03/2013
3	Fatigue 01/2023 - 05/2012
3	Adenocarcinoma 02/2018 - 05/2012
3	Breast Neoplasms (Breast Cancer) 01/2015 - 06/2006
2	Disease Progression 11/2023 - 01/2021
2	Carcinoma (Carcinomatosis) 01/2022 - 10/2012
2	Diarrhea 01/2021 - 05/2012
2	Measles 10/2017 - 01/2015
2	Thrombocytopenia (Thrombopenia) 08/2013 - 05/2012
2	Neutropenia 05/2012 - 06/2006
1	Exanthema (Rash) 01/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023
1	Human Influenza (Influenza) 12/2022
1	Hypertension (High Blood Pressure) 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Alveolar Soft Part Sarcoma 01/2019
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Vesicular Stomatitis 11/2014
1	Stomach Neoplasms (Stomach Cancer) 01/2014
1	Clear-cell metastatic renal cell carcinoma 08/2013
1	Hand-Foot Syndrome 08/2013
1	Starvation 05/2013
1	Lung Neoplasms (Lung Cancer) 03/2013

Drug/Important Bio-Agent (IBA)

7	pembrolizumabIBA 11/2023 - 01/2019
6	Sunitinib (Sutent)FDA Link 01/2023 - 06/2006
5	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2017 - 06/2006
4	Gemcitabine FDA Link 02/2018 - 05/2012
3	enfortumab vedotinIBA 11/2023 - 01/2022
3	belzutifanIBA 11/2023 - 01/2021
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 10/2012
3	lenvatinibIBA 01/2023 - 01/2021
3	Lipase (Acid Lipase)FDA Link 01/2023 - 06/2006
2	Cisplatin (Platino)FDA LinkGeneric 11/2023 - 01/2023
2	Transcription Factors (Transcription Factor)IBA 11/2023 - 01/2021
2	Phosphotransferases (Kinase)IBA 05/2023 - 12/2022
2	Calmodulin (Calcium-Dependent Activator Protein)IBA 05/2023 - 12/2022
2	CalciumIBA 05/2023 - 12/2022
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2021
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 03/2015
2	130-nm albumin-bound paclitaxelIBA 02/2018 - 04/2013
2	Glucose (Dextrose)FDA LinkGeneric 02/2016 - 05/2013
2	Deoxyglucose (2 Deoxy D glucose)IBA 02/2016 - 05/2013
2	folfirinoxIBA 11/2015 - 05/2012
2	Urokinase Plasminogen Activator ReceptorsIBA 01/2015 - 02/2009
2	InterferonsIBA 11/2014 - 08/2013
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2012 - 05/2012
2	Plasminogen Activators (Plasminogen Activator)IBA 10/2012 - 06/2006
2	Peptide Hydrolases (Proteases)FDA Link 10/2012 - 06/2006
1	Hemagglutinins (Hemagglutinin)IBA 12/2022
1	AntigensIBA 12/2022
1	Viral AntigensIBA 12/2022
1	Vaccine AdjuvantsIBA 12/2022
1	SARS-CoV-2 spike proteinIBA 12/2022
1	PlatinumIBA 01/2022
1	Everolimus FDA Link 01/2021
1	Therapeutic UsesIBA 12/2020
1	Immune Checkpoint InhibitorsIBA 01/2019
1	Axitinib (AG 013736)IBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	Albumin-Bound Paclitaxel FDA Link 02/2018
1	ixabepilone (BMS 247550)FDA Link 01/2016
1	Bevacizumab (Avastin)FDA Link 03/2015
1	temsirolimus FDA Link 03/2015
1	LuciferasesIBA 01/2015
1	Trastuzumab (Herceptin)FDA Link 01/2014
1	Epidermal Growth Factor (EGF)IBA 01/2014
1	AnthracyclinesIBA 01/2014
1	pazopanib FDA Link 08/2013
1	Alanine Transaminase (SGPT)IBA 08/2013
1	Cysteine (L-Cysteine)FDA Link 04/2013
1	AcidsIBA 04/2013
1	Proteins (Proteins, Gene)FDA Link 04/2013
1	EnzymesIBA 03/2013
1	15-hydroxyprostaglandin dehydrogenaseIBA 03/2013
1	CytokinesIBA 03/2013
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 03/2013
1	Dinoprostone (PGE2)FDA Link 03/2013
1	Histone Deacetylases (Histone Deacetylase)IBA 03/2013
1	Cetuximab (Erbitux)FDA Link 10/2012
1	Plasminogen Activator Inhibitor 1IBA 10/2012
1	IntegrinsIBA 10/2012
1	Metalloproteases (Metalloproteinases)IBA 10/2012
1	Fluorouracil (Carac)FDA LinkGeneric 05/2012
1	Irinotecan (Camptosar)FDA LinkGeneric 05/2012
1	Leucovorin (Folinic Acid)FDA Link 05/2012

Therapy/Procedure

9	Therapeutics 01/2023 - 06/2005
2	Drug Therapy (Chemotherapy) 01/2014 - 05/2012
1	Combination Drug Therapy (Combination Chemotherapy) 01/2023
1	Castration 01/2023
1	Immunotherapy 12/2022
1	Oncolytic Virotherapy 01/2015
1	Intravenous Administration 01/2015
1	Stents 05/2012